LUCENT biopharma supports new medicines on their route to market

 

We understand the work and dedication required to bring new medicines to market and we apply our world-class expertise to support you at every step of the journey

LUCENT: the experts in commercialising prescription medicines

LUCENT biopharma supports biotech and pharmaceutical companies with clinical-stage products.

 

We design, plan and implement their commercialisation strategy in Europe.

 

We do this using our LUCENT 5-D model:

  1. Medical Affairs

  2. Marketing

  3. Market Access

  4. Field Medical

  5. Omnichannel

medical affairs

Ambitious scientific leadership and implementation - using Real-World Evidence, Implementation Science and early Clinician engagement

market access

Early and collaborative engagement with all levels of the reimbursement  hierarchy - from national bodies to individual payors

omni-channel

Omni-channel enhances, scales and accelerates everything we do 

marketing

Clinically focused strategic marketing based upon a pull, rather than push approach, and independent of any salesforce

field medical

Relentlessly customer facing, scientifically credible and commercially astute - we put your product front-of-mind for the Clinician

Wavy Abstract Background.png

agile & responsive 
product launch

Incredible things happen when you clear a path for effective people who share a passion.

That’s why we’ve built our delivery teams around the LUCENT five domain (5-D) core team and given them complete freedom to operate.

 

No historical or organisational constraints.  Just tailored, agile delivery of your commercial objectives.

Our experiences extend across the prescription medicines life-cycle - from clinical studies to omni-channel engagement, from reimbursement discussions to marketing strategy.

 

Our clients are biotechnology and pharmaceutical businesses of all sizes and shapes, all with a need to launch, commercialise and support their medicines in Europe.

LUCENT by numbers

100

Combined Years of Experience

44

Product Launches

12

Therapeutic Areas

5

Integrated Functions

case studies

Connecting Dots

Training and development for pre-launch European Field Medical Team

Partnering with a pre-launch biotech who were establishing a brand-new European presence, LUCENT undertook detailed analysis of their European MSL capabilities, comparing those with the requirements for the impending first EU launch. What emerged was a detailed and bespoke MSL training and development program, which we delivered over the subsequent months leading up to product launch

Connecting Dots

European reimbursement - Strategic analysis of data availability and gaps

Our US client, with a product launch completed in the US, started with a simple question: ‘What do we need to think about for a European launch of our product’. Taking the lead on the gap and needs analysis for European reimbursement, LUCENT then delivered to them a European Reimbursement Playbook, with a detailed roadmap for achieving reimbursement in each of the EU5

Connecting Dots

Omni-channel strategy, compliance, build and roll-out

Becoming a core part of the in-house technical and marketing team, LUCENT partnered with a newly operational EU biotech to plan, develop, test and build their omni-channel strategy. What emerged over the coming months was an entirely new framework for the compliant delivery of digital content, weaving together web-portals, online webinars and automated delivery of email marketing, all of high clinical value and entirely compliant

Connecting Dots

European forecasting for a Phase 2 asset

As part of early thinking in the planning for a European launch, our client partner asked for a clear, and segmented forecast and scenario plan for the European market, for their Phase 2 asset. Primarily to support in answering the question, ‘Do we out-licence or do we go-it-alone?’ it was as part of this project that the phrase ‘The Third Way’ was first used to describe LUCENT’s approach

Connecting Dots

Pre-launch European strategy development and implementation

As our client-partner awaited regulatory feedback on their MAA in Europe, we were asked to develop a medico-marketing strategy for launch, including strategic pillars, medical imperatives and estimate project plans and budgets for key activities

Connecting Dots

European RWE clinical development planning

Our US clients’ data needs in Europe beyond launch were far-reaching, and built around a single Phase 4 study. LUCENT added a sophisticated suit of RWE gathering exercises in key European countries, including a retrospective analysis of all Phase 2 and 3 databases to deliver new insights to their launch product

Connecting Dots

Phase 3b clinical study design, operationalisation and reporting

Our client-partner asked LUCENT to design and implement a Phase 3b study for a new medicine for their key product – to generate new data on the product and to support it’s regulatory and reimbursement plans. LUCENT designed and set-up the study, including protocol authorship, CRF design, site recruitment and SAP development, ultimately recruiting over 230 patients to treatment

Connecting Dots

European key opinion leader and prescriber network development

The first step for our client following development was the exploration and creation of a key-opinion leader network across Europe. Over-mapping clinical development sites, scientific leadership and likely key-prescribing centres led to the delivery of a KOL network across Europe that entirely belonged to our client

Connecting Dots

Strategic advisory board creation and management

Drawing on the KOL network that we had previously built from scratch, LUCENT developed a highly strategic framework for the gathering of insight, scientific feedback and challenges, and from that established a tiered system of Advisory Board and Scientific Steering Committees for key projects

Connecting Dots

Medical education scientific speaker meetings

LUCENT partnered with its European client to develop and then execute on a range of EU scientific speaker meetings – some associated with key congresses, others stand-alone. Fifteen non-promotional scientific meetings were designed and delivered overall

Connecting Dots

New indication strategic review regulatory application and launch

With a medicine already in market, and an expected new indication available in the next 12 months, our client needed to understand the potential for the new indication in Europe and what would be required to get it there. LUCENT performed this European analysis and proposed a range of scenarios on which they could base their plans for this new launch

are you ready to launch in Europe?

For more information on the services that we offer and how we approach our work, please get in touch.